Millennium Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Millennium Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,000	Closed	-$71.7K	–	6291
2025 Q3	$71.7K	Buy	+10,000	New	+$521K	﹤0.01%	5771
2025 Q1	–	Sell	-10,000	Closed	-$542K	–	6199
2024 Q4	$542K	Buy	+10,000	New	+$511K	﹤0.01%	4692
2024 Q2	–	Sell	-10,200	Closed	-$512K	–	6290
2024 Q1	$512K	Sell	10,200 -17,000	-63%	-$922K	﹤0.01%	4796
2023 Q4	$1.64M	Buy	+27,200	New	+$1.4M	﹤0.01%	3768

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management's MLTX Position: Q1 2026 in Review

Millennium Management reduced its MoonLake Immunotherapeutics (MLTX) stake by 28% in Q1 2026, selling an estimated $3.75M and leaving 576,092 shares worth $10.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2110.

Millennium Management first reported a position in MLTX in Q4 2020 and has held it in 18 quarters since. The position peaked at $13.5M in Q1 2025. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Millennium Management held 576,092 shares of MoonLake Immunotherapeutics worth $10.7M as of Q1 2026.
Millennium Management sold 226,630 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $3.75M.
MoonLake Immunotherapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2110 holding.
Millennium Management first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 18 quarters since.
Millennium Management's MoonLake Immunotherapeutics position peaked at $13.5M in Q1 2025.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.